Wire · operational-macro
Roche's Gazyva Wins FDA Approval For Primary Membranous Nephropathy
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 November 2026 · Fusion42 review
Roche's drug Gazyva has received FDA approval for the treatment of primary membranous nephropathy, marking an important regulatory milestone for this indication in the United States.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 14 Nov 2026 and 16 Nov 2026.
◆ ◆ The Wire takeaway
You now have a new approved treatment option in kidney disease from Roche. This FDA green light opens the door for competitive innovation or partnership in primary membranous nephropathy therapy.
◆ Coverage
2 sources · first reported 14 Nov 2026 · latest 16 Nov 2026
◆ Related on Wire
◆ Topics